论文信息 - Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.

Balancing the benefits and risks of inhaled long-acting beta-agonists--the influence of values.

In December 2008, the FDA reviewed the risks and benefits of inhaled long-acting beta-agonists for the treatment of asthma in adults and children. Dr. Judith Kramer writes that the challenge of protecting the public's health is heightened by variability in the values placed on benefits and risks.

J. Kramer | Judith M. Kramer

[1] F. Martinez. Safety of long-acting beta-agonists--an urgent need to clear the air. , 2005, The New England journal of medicine.

[2] J. Drazen,et al. Risks of long-acting beta-agonists in achieving asthma control. , 2009, The New England journal of medicine.

[3] P. Dorinsky,et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. , 2006, Chest.